Comparison of clinical and pathologic findings of prostate cancers detected through screening versus conventional referral in Brazil

Clinical Genitourinary Cancer

Volumn 9, Issue 2, 2011, Pages 104-108

  Faria, Eliney F ^a,b   Carvalhal, Gustavo F ^a   Vieira, René A ^a   Silva, Thiago B ^a   Mauad, Edmundo C ^a   Tobias Machado, Marcos ^a   Carvalho, André L ^a,b  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAZIL; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL EXAMINATION; COMPARATIVE STUDY; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROSTATE CANCER; REGIONAL METASTASIS;

AGED; AGED, 80 AND OVER; BRAZIL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 80055032771     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.06.004     Document Type: Article

References (34)

1. M.P. Coleman, M. Quaresma, and F. Berrino Cancer survival in five continents: a worldwide population-based study (CONCORD) Lancet Oncol 9 2008 730 756
2. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. J.B. Shah, J.M. McKiernan, and E.P. Elkin Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy J Urol 179 2008 136 140 (Pubitemid 350225691)
4. K. Zhu, S.S. Devesa, and H. Wu Cancer incidence in the U. S. military population: comparison with rates from the SEER program Cancer Epidemiol Biomarkers Prev 18 2009 1740 1745
5. J.S. Krumholtz, G.F. Carvalhal, and C.G. Ramos Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 473 discussion 473-4 (Pubitemid 35292175)
6. S. Loeb, C.M. Gonzalez, and K.A. Roehl Pathological characteristics of prostate cancer detected through prostate specific based screening J Urol 175 2006 902 906 (Pubitemid 43200014)
7. W.J. Catalona Prostate cancer screening BJU Int 94 2004 964 966 (Pubitemid 39577074)
8. G. Bartsch, W. Horninger, and H. Klocker Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria Urology 58 2001 417 424 (Pubitemid 32816361)
9. C. Bouchardy, G. Fioretta, and E. Rapiti Recent trends in prostate cancer mortality show a continuous decrease in several countries Int J Cancer 123 2008 421 429 (Pubitemid 351842029)
10. G.L. Andriole, E.D. Crawford, and R.L. Grubb 3rd Mortality results from a randomized prostate-cancer screening trial [erratum in 2009; 360:1797] N Engl J Med 360 2009 1310 1319
11. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
12. M.J. Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
13. J.A. Lane, F.C. Hamdy, and R.M. Martin Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies Eur J Cancer 46 2010 3095 3101
14. P.J. van Leeuwen, D. Connolly, and A. Gavin Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit Eur J Cancer 46 2010 377 383
15. S.E. Oliver, D. Gunnell, and J.L. Donovan Comparison of trends in prostate-cancer mortality in England and Wales and the USA [erratum in 2000; 356:1278] Lancet 355 2000 1788 1789 (Pubitemid 30265086)
16. E.F. Faria, G.F. Carvalhal, and R.A. Vieira Program for prostate cancer screening using a mobile unit: results from Brazil Urology 76 2010 1052 1057
17. INCA/Brasil, Tipos de Cncer Próstata Ministério da Sade. Secretaria de Assistência Sade http://www.inca.gov.br/estimativa/2010/ index.asp?link=tabelaestados.asp&UF=BR 2010 Accessed July 27, 2011
18. F.L. Greene, D. Page, and M. Morrow AJCC Cancer Staging Handbook 6th edition 2002 Springer New York
19. C.D. Scales Jr, J. Antonelli, and L.H. Curtis Prostate-specific antigen screening among young men in the United States Cancer 113 2008 1315 1323
20. S. Ciatto, M. Zappa, and A. Villers Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening BJU Int 92 Suppl 2 2003 97 100 (Pubitemid 38091150)
21. N.V. Desireddi, K.A. Roehl, and S. Loeb Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era Urology 70 2007 950 955 (Pubitemid 350192577)
22. A. Gallina, C. Jeldres, and F.K. Chun Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL Eur Urol 52 2007 1374 1380 (Pubitemid 47445969)
23. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis J Natl Cancer Inst 101 2009 878 887
24. J.A. Efstathiou, M.H. Chen, and W.J. Catalona Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality Urology 68 2006 342 347 (Pubitemid 44202546)
25. W.J. Catalona, C.G. Ramos, and G.F. Carvalhal Contemporary results of anatomic radical prostatectomy CA Cancer J Clin 49 1999 282 296 (Pubitemid 30142821)
26. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 269 274
27. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439 (Pubitemid 41124175)
28. J.W. Moul, V. Mouraviev, and L. Sun Prostate cancer: the new landscape Curr Opin Urol 19 2009 154 160
29. I.W. van der Cruijsen-Koeter, A.N. Vis, and M.J. Roobol Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam J Urol 174 2005 121 125 (Pubitemid 40825690)
30. I.W. van der Cruijsen-Koeter, M.J. Roobol, and M.F. Wildhagen Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam Urology 68 2006 615 620 (Pubitemid 44436477)
31. W.J. Catalona, and S. Loeb Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values J Natl Compr Canc Netw 8 2010 265 270
32. R. Etzioni, J.M. Legler, and E.J. Feuer Cancer surveillance series: interpreting trends in prostate cancer - part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality J Natl Cancer Inst 91 1999 1033 1039 (Pubitemid 29293042)
33. S.L. Galper, M.H. Chen, and W.J. Catalona Evidence to support a continued stage migration and decrease in prostate cancer specific mortality J Urol 175 2006 907 912 (Pubitemid 43200015)
34. R. Postma, F.H. Schröder, and G.J. van Leenders Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam A comparison of two rounds of screening Eur Urol 52 2007 89 97 (Pubitemid 46803013)